Skip to main content

Table 1 Cohort demographics

From: Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels

 

Knight ADRC

ADNI1

ADNI2

BIOCARD

HB

Mayo

Sweden

UPenn

UW

n = 3146

805

390

397

184

105

433

293

164

375

Age (years)

70.39 ± 9.12

77.89 ± 6.89

73.28 ± 7.47

62.10 ± 9.46

67.52 ± 9.24

78.73 ± 6.35

75.15 ± 7.63

71.60 ± 8.98

62.35 ± 16

Age range (years)

37–91

58–93

55–92

23–86

45–84

50–95

50–88

50–94

21–88

Male (%)

46.09

60

54.91

41.53

54.29

60.51

37.54

41.46

50.67

APOE ε4 positive (%)

40.75

50

38.29

34.43

54.29

27.5

76.11

55.56

43.28

CDR > 0 (%)

29.34

71.28

71.03

5.43

22.17

100

62.8

33.33

42 levelsa

650.40 ± 305.59

169.83 ± 56.0

179.98 ± 51.31

386.90 ± 89.93

77.59 ± 23.30

331.0 ± 122.21

262.43 ± 72.77

163.55 ± 53.54

141.90 ± 41.42

p-tau181 levelsa

64.94 ± 34.26

34.13 ± 18.52

38.63 ± 21.21

38.94 ± 12.30

23.16 ± 10.55

105.76 ± 41.82

36.96 ± 26.80

56.56 ± 29.32

tau levelsa

372.40 ± 235.41

97.26 ± 52.03

79.69 ± 47.79

66.56 ± 26.60

84.27 ± 36.79

104.29 ± 58.06

782.20 ± 301.68

93.66 ± 54.29

61.64 ± 42.77

  1. aReported as mean ± standard deviation in pg/mL
  2. ADRC Alzheimer’s Disease Research Center, ADNI Alzheimer’s Disease Neuroimaging Initiative, APOE apolipoprotein E, BIOCARD Predictors of Cognitive Decline Among Normal Individuals, CDR Clinical Dementia Rating, HB Saarland University in Homburg/Saar, Germany, Mayo Mayo Clinic, Sweden Sahlgren’s University Hospital, Sweden, UPenn Perelman School of Medicine at the University of Pennsylvania, UW University of Washington